Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review
Genes · 2023
DOI: 10.3390/genes14081572 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Genes, 2023. Verfasst von Ruolin Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie, ERC-Advanced Grant LEGENDARE.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Although common drugs for treating type 2 diabetes (T2D) are widely used, their therapeutic effects vary greatly. The interaction between the gut microbiome and glucose-lowering drugs is one of the main contributors to the variability in T2D progression and response to therapy. On the one hand, glucose-lowering drugs can alter gut microbiome components. On the other hand, specific gut microbiota can influence glycemic control as the therapeutic effects of these drugs. Therefore, this systematic review assesses the bi-directional relationships between common glucose-lowering drugs and gut microbiome profiles.
Methods
A systematic search of Embase, Web of Science, PubMed, and Google Scholar databases was performed. Observational studies and randomised controlled trials (RCTs), published from inception to July 2023, comprising T2D patients and investigating bi-directional interactions between glucose-lowering drugs and gut microbiome, were included.
Results
Summarised findings indicated that glucose-lowering drugs could increase metabolic-healthy promoting taxa (e.g., Bifidobacterium) and decrease harmful taxa (e.g., Bacteroides and Intestinibacter). Our findings also showed a significantly different abundance of gut microbiome taxa (e.g., Enterococcus faecium (i.e., E. faecium)) in T2D patients with poor compared to optimal glycemic control.
Conclusions
This review provides evidence for glucose-lowering drug and gut microbiome interactions, highlighting the potential of gut microbiome modulators as co-adjuvants for T2D treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
- Department of Epidemiology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
- Department of Data Science & Biostatistics, Julius Global Health, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
ORCID-Profile: Ruolin Li, Fereshteh Shokri, Fariba Ahmadizar
Förderung
- European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie
- ERC-Advanced Grant LEGENDARE
Zitieren
APA
Li, R., Shokri, F., Rincon, A. L., Rivadeneira, F., Medina-Gomez, C., & Ahmadizar, F. (2023). Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review. Genes. https://doi.org/10.3390/genes14081572
Vancouver
Li R, Shokri F, Rincon AL, Rivadeneira F, Medina-Gomez C, Ahmadizar F. Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review. Genes. 2023. doi:10.3390/genes14081572
BibTeX
@article{Li2023,
author = {Li, Ruolin and Shokri, Fereshteh and Rincon, Alejandro Lopez and Rivadeneira, Fernando and Medina-Gomez, Carolina and Ahmadizar, Fariba},
title = {Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14081572}
}
EUVIMED